Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Imke Atreya

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Expert Review of Anticancer Therapy|April 12, 2008
Immune cells in colorectal cancer: prognostic relevance and therapeutic strategiesImke Atreya, Markus F Neurath
Gut|August 26, 2016
Microbiota: relevant player in thiopurine metabolisation?Imke Atreya, Markus F Neurath
Gut|February 13, 2009
Understanding the delayed onset of action of azathioprine in IBD: are we there yet?Imke Atreya, Markus F Neurath
Expert Review of Gastroenterology & Hepatology|December 17, 2008
Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implicationsImke Atreya, Markus F Neurath
Biomedicines|November 26, 2022
How the Tumor Micromilieu Modulates the Recruitment and Activation of Colorectal Cancer-Infiltrating LymphocytesImke Atreya, Markus F Neurath
Signal Transduction and Targeted Therapy|June 8, 2024
Linking IL-10 signaling with lipid metabolic programs in macrophages: dysregulated ceramide homeostasis drives colitisImke Atreya, Markus F Neurath
Seminars in Immunology|February 18, 2019
Innate lymphoid cells in intestinal cancer developmentImke Atreya, Markus Kindermann, Stefan Wirtz
Inflammatory Bowel Diseases|February 26, 2013
Targeted inhibition of Vav1 activity does not favour development of colitis-associated colon cancerStefanie Zenker, Markus F Neurath, Imke Atreya
Cellular and Molecular Life Sciences : CMLS|September 15, 2016
Molecular pathways driving disease-specific alterations of intestinal epithelial cellsRocío López-Posadas, Markus F Neurath, Imke Atreya
Seminars in Immunopathology|April 7, 2018
ILC2s in infectious diseases and organ-specific fibrosisMarkus Kindermann, Lisa Knipfer, Imke Atreya, et al.
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Expert Review of Anticancer Therapy|April 12, 2008
Immune cells in colorectal cancer: prognostic relevance and therapeutic strategiesImke Atreya, Markus F Neurath
Gut|August 26, 2016
Microbiota: relevant player in thiopurine metabolisation?Imke Atreya, Markus F Neurath
Gut|February 13, 2009
Understanding the delayed onset of action of azathioprine in IBD: are we there yet?Imke Atreya, Markus F Neurath
Expert Review of Gastroenterology & Hepatology|December 17, 2008
Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implicationsImke Atreya, Markus F Neurath
Biomedicines|November 26, 2022
How the Tumor Micromilieu Modulates the Recruitment and Activation of Colorectal Cancer-Infiltrating LymphocytesImke Atreya, Markus F Neurath
Signal Transduction and Targeted Therapy|June 8, 2024
Linking IL-10 signaling with lipid metabolic programs in macrophages: dysregulated ceramide homeostasis drives colitisImke Atreya, Markus F Neurath
Seminars in Immunology|February 18, 2019
Innate lymphoid cells in intestinal cancer developmentImke Atreya, Markus Kindermann, Stefan Wirtz
Inflammatory Bowel Diseases|February 26, 2013
Targeted inhibition of Vav1 activity does not favour development of colitis-associated colon cancerStefanie Zenker, Markus F Neurath, Imke Atreya
Cellular and Molecular Life Sciences : CMLS|September 15, 2016
Molecular pathways driving disease-specific alterations of intestinal epithelial cellsRocío López-Posadas, Markus F Neurath, Imke Atreya
Seminars in Immunopathology|April 7, 2018
ILC2s in infectious diseases and organ-specific fibrosisMarkus Kindermann, Lisa Knipfer, Imke Atreya, et al.
Pageof 8